Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ZIOP $3.09 0.2880 +10.29%
ADXS $3.35 0.2700 +8.77%
VSTM $9.65 0.6900 +7.70%
TGTX $10.75 0.7000 +6.97%
VRML $1.64 0.0900 +5.81%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CPXX $2.12 -0.1300 -5.78%
CYTR $2.76 -0.1500 -5.15%
DNDN $1.00 -0.0400 -3.85%
CRIS $1.30 -0.0500 -3.70%
OMED $20.52 -0.5700 -2.70%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Researchers Reveal Genomic Diversity of Individual Lung Tumors

(MD Anderson) Oct 9, 2014 - Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science.
read press release 

Scientists Find Lung Cancer Can Lie Hidden For 20 Years

(Reuters) Oct 9, 2014 - Lung cancer can lie dormant for more than 20 years before turning deadly, helping explain why a disease that kills more than 1.5 million a year worldwide is so persistent and difficult to treat, scientists said on Thursday.
read article 

FDA Approves Akynzeo For Nausea and Vomiting Associated With Cancer Chemotherapy

( Oct 10, 2014 - The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
read press release 

FDA Approves Bortezomib (Velcade) For Untreated MCL

(Medscape Medical News) Oct 9, 2014 - The US Food and Drug Administration (FDA) today approved bortezomib (Velcade; Millennium) for previously untreated patients with mantle cell lymphoma (MCL).
read article (free registration required) 

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation in Acute Lymphoblastic Leukemia

(Amgen) Oct 9, 2014 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab.
read corporate press release 

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

(Yahoo! Finance) Oct 9, 2014 - Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved VELCADE® (bortezomib) for injection for use in previously untreated patients with mantle cell lymphoma (MCL).
read article 

FDA Panel Offers Mixed View on Boston Scientific Watchman Device

(Reuters) Oct 8, 2014 - An advisory panel to the U.S. Food and Drug Administration offered a mixed view of Boston Scientific Corp's Watchman heart device on Wednesday, concluding it is probably safe but not particularly effective in reducing the risk of stroke in patients with a certain type of irregular heart beat.
read article 

Endo to Buy Auxilium For $2.6 Billion to Gain Men’s Drugs

(Bloomberg) Oct 9, 2014 - Endo International Plc agreed to buy Auxilium Pharmaceuticals Inc. for about $2.6 billion to gain testosterone products.
read article 

A Tale of Two Ebola Stocks: Chimerix and Tekmira

(CNBC) Oct 9, 2014 - The Ebola story has played out in the stock market recently largely on the backs of two companies: drugmakers Chimerix and Tekmira.
read article 

Gene-Therapy Trial Shows Promise Fighting ‘Bubble Boy’ Syndrome

(TIME) Oct 9, 2014 - A new gene-therapy treatment is showing promise in treating a rare and severe congenital condition that involves extreme immune-system deficiencies.
read article 

Woman With Cancer Plans to Take Her Life in Oregon

(ABC News/Associated Press) Oct 9, 2014 - Brittany Maynard will not live to see if her advocacy makes a difference.
read article 

ASCO Joins Effort Urging CMS to Provide Medicare Coverage for LDCT Lung Cancer Screening

(ASCO in Action) Oct 9, 2014 - On September 26, 2014, ASCO joined other leading medical organizations in signing a letter to the Centers for Medicare & Medicaid Services (CMS) in support of full Medicare coverage for annual low-dose computed tomography (LDCT) scans in adults ages 55 to 80 years, who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.
read article 

FDA Posts Draft Guidance on Laboratory-Developed Tests

(ASCO in Action) Oct 8, 2014 - The Food and Drug Administration (FDA) published on its website a Draft Guidance proposing a risk-based phased-in framework for oversight of laboratory developed tests (LDTs) that place patients at greater risk for harm if their results are not accurate, and an accompanying draft guidance that describes the notification process for LDTs and the Medical Device Reporting (MDR) requirements.
read article 

Phase 3 Trial Now Recruiting For Treatment of Rare Bile Duct Cancer

(Healio) Oct 8, 2014 - A university in Germany has begun recruiting patients for a phase 3 clinical trial to study the safety and efficacy of photodynamic therapy with porfimer sodium to treat a rare form of bile duct cancer, according to a press release.
read article (free registration required) 

Biofrontera Set For US Approval Application For Ameluz in Early 2015

(Morningstar/Alliance News) Oct 8, 2014 - Biopharmaceutical company Biofrontera AG Wednesday said that it had a pre-new drug application meeting with the US Food & Drug Administration regarding the approval process for its Ameluz and BF-RhodoLED skin cancer treatment in the US, and all the questions raised were answered as proposed by the company.
read article 

Regen Files IND Application For dCellVax With FDA to Treat Breast Cancer

(Pharmaceutical Business Review) Oct 9, 2014 - Regen BioPharma has filed an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to begin a clinical trial evaluating safety and therapeutic effects of its immunotherapeutic product, dCellVax, to treat patients with metastatic breast cancer.
read article 

New Guidelines Issued on Bowel Prep For Colonoscopy

(Medscape Medical News) Oct 8, 2014 - With up to 25% of all colonoscopies reported as having an inadequate bowel preparation, the US Multi-Society Task Force on Colorectal Cancer has published new consensus guidelines aimed at raising the preparation compliance goal to at least 85%.
read article (free registration required) 

Cancer Care Is Advancing, But Costs Cannot Be Ignored

(Yahoo! Finance) Oct 8, 2014 - Cancer care is advancing, but policymakers and the cancer care community must find ways to make it more affordable, according to an article published in the October issue of Health Affairs by Lee N. Newcomer, M.D., senior vice president of oncology at UnitedHealthcare.
read article 

CytRx Initiates Phase 1b Clinical Trial With Combination of Aldoxorubicin and Gemcitabine in Patients With Metastatic Solid Tumors

(Yahoo! Finance) Oct 9, 2014 - CytRx Corporation today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.
read article 

GenSpera Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients

(TheStreet) Oct 9, 2014 - GenSpera, Inc. today announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer (hepatocellular carcinoma). Formal results of the study are expected to be available during the first quarter of 2015.
read article 

Cancer Drug Made From Rainforest Plant Shows Promise, Study Says

( Oct 8, 2014 - Researchers in Australia have used an experimental drug made from the seeds of a rainforest plant to cure solid tumors in head, neck and colon cancer models.
read article 

Neuroscientists Use Snail Research to Help Explain “Chemo Brain”

(UT Health Science Center Houston) Oct 1, 2014 - It is estimated that as many as half of patients taking cancer drugs experience a decrease in mental sharpness. While there have been many theories, what causes “chemo brain” has eluded scientists.
read press release 

Discovery May Lead to Lower Doses of Chemotherapy

(BYU) Oct 8, 2014 - No matter what type of chemotherapy you attack a tumor with, many cancer cells resort to the same survival tactic: They start eating themselves.
read press release 

New Clues For Early Colorectal Cancer Detection

(University of Luxembourg) Oct 9, 2014 - The Luxembourg-based team were the first to see a significant reduction in certain proteins (specifically SOCS2 and SOCS6) in pre-cancerous and cancerous colorectal cells. They concluded that especially SOCS2 could be a very sensitive, early diagnostic biomarker.
read press release 

Study Finds Potential Link Between Breast Cancer Genes and Salivary Gland Cancer

(OSUCCC - James) Oct 7, 2014 - The risk of developing cancer in a salivary gland might be higher in people with mutations in either of two genes associated with breast and ovarian cancer, according to a new study.
read press release